Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)

NCT00286793 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.

NCT NCT00286793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00286793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase I/II Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer (HRPC)
Lead sponsor
Ascenta Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2006
Completion date
November 30, 2009
Enrollment
76 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer